Logo

Top 20 Immunology Companies Based on 2021 Immunology Segment Revenue

Share this
Top 20 Immunology Companies Based on 2021 Immunology Segment Revenue

Top 20 Immunology Companies Based on 2021 Immunology Segment Revenue

Shots:

  • Immunology focuses on analyzing all aspects of the immune system in both healthy and diseased states, from its structure & function to its disorders, blood banking, immunization & organ transplant
  • Along with the enhanced utilization of immunotherapies for immunological & autoimmune diseases, monoclonal antibodies have also showcased a great potential to be used as a treatment option. As in 2021, Abbvie again secured the top position with total revenue of $25.24B, followed by J&J, Roche, and Amgen
  • Our team at PharmaShots has compiled a list of the top 20 immunology companies based on their 2021 immunology revenue

Immunology Segment Revenue: $0.014B

Founded Year: 1979

Market Cap: N/A

Total Employees: ~200

Headquarters: New Jersey, United States

Stock Exchange: NASDAQ

Antares Pharma is a pharmaceutical company that develops pharmaceutical products and technologies including needle-free and mini-needle injector systems and transdermal gel technologies. Otrexup was the key player in its immunology segment generating the total revenue. Antares Pharma’s 2021’s revenue declined by 6.67% vs. 2020. On Dec’21 Antares Pharma’s Otrexup was acquired by Assertio Holdings to advance its product pipeline whereas in May’22 Antares Pharma was acquired by Halozyme Therapeutics.

Immunology Segment Revenue: $0.12B

Founded Year: 1993

Market Cap: $1.61B

Total Employees: ~5,290

Headquarters: Shenyang, China

Stock Exchange: HKG

3S Bio is a Chinese Biotechnology company that develops and commercializes biopharmaceutical products along with recombinant or genetically engineered, protein-based products in the areas of oncology, nephrology, dermatology, and auto-immune diseases. 3S bio immunology segment is boosted by the sales of its lead product, Yisaipu. 3S Bio’s 2021 revenue increased by 33.30% vs. 2020. On Dec’21, 3SBio expanded its partnership with Numab for the development and commercialization of NM28.

Immunology Segment Revenue: $0.81B

Founded Year: 2007

Market Cap: $0.008B

Total Employees: ~6,700

Headquarters: Osaka, Japan

Stock Exchange: TYO

Mitsubishi Tanabe Pharma is a pharmaceutical company dedicated towards providing therapeutic options across areas including Diabetes, Kidney Diseases, Autoimmune Diseases & Vaccines. The products contributing to the company’s immunology segment are Stelera, Simponi & Imusera. Mitsubishi’s 2021 revenue was boosted by 14.08% vs. 2020. On Jan’21, Mitsubishi joined forces with Pharma Foods International to develop a therapeutic antibody for autoimmune diseases.

Immunology Segment Revenue: $1.12B

Founded Year: 1891

Market Cap: $226.38B

Total Employees: ~68,000

Headquarters: New Jersey, United States

Stock Exchange: NYSE

Merck & Co. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biological therapies & animal health products. The company’s immunology segment includes Simponi & Remicade. Merck’s 2021 revenue was reduced by 3.45% vs. 2020. On Nov’21, Merck and Synthekine partnered to discover novel cytokine therapeutics utilizing Synthekine’s surrogate cytokine agonist platform.

Immunology Segment Revenue: $1.19B

Founded Year: 2000

Market Cap: $79.64B

Total Employees: ~91,960

Headquarters: Surrey, United Kingdom

Stock Exchange: LON

GSK is a global healthcare multinational company involved in the development, manufacture, and marketing of pharmaceutical products, vaccines, OTC medicines, and health-related consumer products. The immunology segment was one of the main drivers of its 2021 revenue. GSK’s 2021 revenue was boosted by 13.33% vs. 2020. On Jun’21 GSK collaborated with Progentec to analyse proteomics & digital health tools for Lupus.

Immunology Segment Revenue: $1.53B

Founded Year: 1923

Market Cap: $0.02B

Total Employees: ~14,520

Headquarters: Tokyo, Japan

Stock Exchange: TYO

Astellas is a Japanese pharmaceutical company that focuses on all therapeutic areas including Cardiology, Hematology, Immunology, Infectious Diseases, Oncology & Urology. The company’s net immunology revenue was generated through its product Prograf. Astellas’ 2021 revenue decreased by 7.27% vs. 2020. On Jul’21, the US FDA approved the sNDA for Astellas’ Prograf to prevent organ rejection in adult and pediatric lung transplant recipients.

Immunology Segment Revenue: $2.06B

Founded Year: 1978

Market Cap: $31.87B

Total Employees: ~9,610

Headquarters: Massachusetts, United States

Stock Exchange: NASDAQ

Biogen is a global biopharmaceutical company that provides therapies for autoimmune, neurological & neurodegenerative diseases. The company’s immunotherapy includes TYSABRI as a treatment option for autoimmune diseases. Biogen’s 2021 revenue showcased an increment of 6.18% vs. 2020. On Jul’21, Biogen settled for a license & collaboration agreement with Innocare for Orelabrutinib.

Immunology Segment Revenue: $2.07B

Founded Year: 2008

Market Cap: $15.46B

Total Employees: ~1,890

Headquarters: Dublin, Ireland

Stock Exchange: NASDAQ

Horizon Therapeutics is a biopharmaceutical company that targets the discovery, development & commercialization of medicines for autoimmune & severe inflammatory diseases. The net sale of the company’s immunology segment was based on the sales of Tepezza, Rayos, Duexis, Vimovo & Pennsaid. Horizon’s 2021 revenue was inclined by 68.29% vs. 2020. On Dec’21, Horizon Therapeutics collaborated with Alpine Immune Sciences to develop protein-based therapies for autoimmune & inflammatory diseases

Immunology Segment Revenue: $2.09B

Founded Year: 1928

Market Cap: $3.44B

Total Employees: ~8,560

Headquarters: Brussels, Belgium

Stock Exchange: EBR

UCB is a biopharmaceutical company dedicated to the development of products based on therapeutic areas including CNS &Immunology. Under the company’s immunotherapies Cimzia ($2.0B) had more contribution to the total revenue. UCB’s 2021 revenue was reduced by 4.57% vs. 2020. On Feb’21, UCB collaborated with Microsoft to accelerate drug discovery & development under its immunology & neurology segments.

Immunology Segment Revenue: $2.13B

Founded Year: 2002

Market Cap: $16.40B

Total Employees: ~2,090

Headquarters: Delaware, United States

Stock Exchange: NASDAQ

Incyte is a biopharmaceutical company focused on the discovery, development & commercialization of proprietary therapeutics across therapeutic areas including Hematology, Oncology, Inflammation & Autoimmunity. The company’s net revenue was generated through its immunotherapy Jakafi. Incyte’s 2021 revenue was boosted by 10.36% vs. 2020. On Sep’21 Incyte entered into a collaboration with Syndax for the development & commercialization of Axatilimab to treat cGvHD & other fibrotic diseases.

Immunology Segment Revenue: $3.31B

Founded Year: 1887

Market Cap: $160.06B

Total Employees: ~32,200

Headquarters: New York, United States

Stock Exchange: NYSE

Bristol-Myers Squibb (BMS) is a pharmaceutical company that focuses on oncology, cardiovascular & immunological diseases. The immunological segment of the company contains Orencia. BMS’s 2021 revenue was boosted by 4.75% vs. 2020. On Aug’21, BMS in-licensed Exscientia’s immune-modulating drug candidate for multiple therapeutic areas including immunology & oncology  

Immunology Segment Revenue: $3.36B

Founded Year: 1876

Market Cap: $287.92B

Total Employees: ~35,000

Headquarters: Indiana, United States

Stock Exchange: NYSE

Eli Lilly is a pharmaceutical company that focuses on the development, manufacturing & marketing of pharmaceutical products across immunology, neurodegenerative diseases & endocrinology. The company provides Taltz & Olumiant under its immunotherapies. Eli Lilly’s 2021 revenue showcased a hike of 36.58% vs. 2020. In Feb’21, Lilly and Rigel joined forces to develop RIPK1 Inhibitors for Immunological & Neurodegenerative Diseases.

Immunology Segment Revenue: $3.8B

Founded Year: 1781

Market Cap: $46.18B

Total Employees: ~47,000

Headquarters: Tokyo, Japan

Stock Exchange: NYSE

Takeda is a Japanese multinational biopharmaceutical company with its main target area including Metabolic Disorders, Gastroenterology, Neurology, Inflammation, Immunology & Oncology. The company’s approved immunotherapies include Immunoglobulin & Albumin. Takeda’s 2021 revenue escalated by 6.74% vs. 2020. On Sep’21, MHLW (Japan) granted Takeda’s Alofisel a manufacturing & marketing approval in Japan to treat Non-active or Mildly Active Luminal Crohn’s Disease.

Immunology Segment Revenue: $4.43B

Founded Year: 1849

Market Cap: $2.40B

Total Employees: ~79,000

Headquarters: New York, United States

Stock Exchange: NYSE

Pfizer is a global pharmaceutical company that discovers, develops, manufactures & distributes biopharmaceutical products for immunology, oncology, cardiology, endocrinology & neurology. Among the company’s immunotherapies, Xeljanz has generated $2.45B in revenue from the overall revenue. Pfizer’s 2021 revenue declined by 3% vs. 2020. On Jan’21, Pfizer made a $25M investment in Vedanta as a part of its Breakthrough Growth Initiative.

Immunology Segment Revenue: $5.78B

Founded Year: 1996

Market Cap: $210.35B

Total Employees: ~108,000

Headquarters: Basel, Switzerland

Stock Exchange: SWX

Novartis is a multinational pharmaceutical company that targets therapeutic areas including Immunology, Dermatology, Cardio-Metabolic, Oncology, Neurology & Ophthalmology. The company’s immunology segment includes Cosentyx & Ilaris along with other immunotherapies. Novartis’ 2021 revenue was raised by 18.90% vs. 2020. On Oct’21, Novartis entered into a strategic partnership with Innodem Neurosciences to conduct a breakthrough clinical trials.

Immunology Segment Revenue: $6.3B

Founded Year: 1973

Market Cap: $1.86B

Total Employees: ~95,440

Headquarters: Paris, France

Stock Exchange: NASDAQ

Sanofi is a global healthcare provider of solutions across various countries focused on the therapeutic area including, CVD, Neurology, Diabetes, Internal Medicine, Oncology, Thrombosis & Vaccines. The company’s immunotherapies Dupixent ($5.25B) & Kevzara ($0.29B) have contributed to its immunology revenue. Sanofi’s 2021 revenue increased by 36.96% vs. 2020. In Apr’21, Sanofi acquires Tidal Therapeutics to utilize Tidal’s mRNA-based research platform to expand its immunology & oncology segments.

Immunology Segment Revenue: $6.71B

Founded Year: 1980

Market Cap: $132.67B

Total Employees: ~24,200

Headquarters: California, United States

Stock Exchange: NASDAQ

Amgen is a biotechnology company that provides treatment options for diseases including, CVD, oncology, bone health, neuroscience, immunology, nephrology & inflammation. The total sale obtained by the company included the sales Enbrel & Otezla. Amgen’s 2021 revenue decreased by 6.67% vs. 2020. On Jun’21, Amgen and Kyowa Kirin collaborated to jointly develop and commercialize KHK4083 to treat Atopic Dermatitis.

Immunology Segment Revenue: $8.89B

Founded Year: 1896

Market Cap: $278.79B

Total Employees: ~100,920

Headquarters: Basel, Switzerland

Stock Exchange: SWX

Roche is a Swiss-based multinational healthcare company that functions under two divisions, Pharmaceutical & Diagnostics. The company’s immunology section delivers products for rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis & giant cell arteritis. Its immunotherapy Actemra contributed a sale of $3.78B to the overall sale. Roche’s 2021 revenue increased by 3.98% vs. 2020. On Jun’21 Roche entered into a research collaboration with Synlogic to develop novel therapies for inflammatory bowel diseases.

Immunology Segment Revenue: $16.75B

Founded Year: 1886

Market Cap: $447.43B

Total Employees: ~141,700

Headquarters: New Jersey, United States

Stock Exchange: NYSE

Johnson & Johnson (J&J) is an American multinational healthcare company that delivers products in therapeutic areas including Neuroscience, Oncology, Immunology, Cardiovascular, Metabolism & Pulmonary Hypertension. Under its Immunological segment, the company focuses on diseases including rheumatoid arthritis, inflammatory bowel diseases & psoriasis. J&J’s 2021 revenue increased by 11.29% vs. 2020. Stelara generated $9.13B in revenue from the overall sale in its immunology segment. In Apr’21, J&J submitted an MAA to EMA for the approval of BCMA CAR-T therapy cilta-cel to treat multiple myeloma.

Immunology Segment Revenue: $25.24B

Founded Year: 2013

Market Cap: $247.84B

Total Employees: ~50,000

Headquarters: New York, United States

Stock Exchange: NYSE

Abbvie is a biopharmaceutical company focused on the development of products across key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics & eye care. The company’s immunological segment includes Humira, Skyrizi & Rinvoq from which Humira individually generated revenue of $20.69B out of Abbvie’s total sales. AbbVie's 2021 revenue increased by 14.13% vs. 2020. On Jan’21, Abbvie’s Rinvoq received the EU approval for the treatment of Psoriatic Arthritis and Ankylosing Spondylitis.

Sources:

  • Annual reports
  • SEC filings
  • Press releases
  • Company websites

Market Cap Source: Google finance (10th August, 2022)

Currency Conversion: X-Rates (10th August, 2022)

Note:

  • All revenues are reported in $B
  • The revenue for Astellas increased in JPY by 1.48% but decreased in USD due to the currency rate drop
  • The revenue for UCB increased in EUR by 2.56% but decreased in USD due to the currency rate drop

Related Post: Top 20 Immunology Companies Based on 2020 Immunology Segment Revenue


Shivani

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions